Harmony Biosciences Holdings, Inc.

HRMY

US4131971040

Pharmaceuticals

Market Closed - Nasdaq Other stock markets 16:00:00 2024-06-27 EDT			5-day change	1st Jan Change
31.48 ^USD	+1.29%		+9.27%	-2.54%

06-25	Harmony Biosciences Holdings, Inc. Announces U.S. Food & Drug Administration Action Deny the Citized Petition for WAKIX®?	CI
06-24	Harmony Biosciences Says FDA Approves Supplemental NDA for Pediatric Narcolepsy Treatment	MT

Harmony Biosciences Holdings, Inc. Reaffirms Sales Guidance for the Year 2024

June 10, 2024 at 09:20 am

Harmony Biosciences Holdings, Inc. reaffirmed sales guidance for the year 2024. For the year, the company expects sales to be between $700 million to $720 million.

Latest news about Harmony Biosciences Holdings, Inc.

Harmony Biosciences Holdings, Inc. Announces U.S. Food & Drug Administration Action Deny the Citized Petition for WAKIX®?	06-25	CI
Harmony Biosciences Says FDA Approves Supplemental NDA for Pediatric Narcolepsy Treatment	06-24	MT
Harmony Biosciences Receives U.S. Food and Drug Administration Approval for WAKIX in Pediatric Patients with Narcolepsy	06-24	CI
Citigroup Initiates Harmony Biosciences at Buy Rating With $48 Price Target	06-21	MT
Harmony Biosciences Holdings, Inc. Reaffirms Sales Guidance for the Year 2024	06-10	CI
Transcript : Harmony Biosciences Holdings, Inc. Presents at Goldman Sachs 45th Annual Global Healthcare Conference, Jun-10-2024 09:20 AM	06-10
HARMONY Biosciences Presents Positive Data for Pitolisant in the Treatment of Excessive Daytime Sleepiness and FATIGUE in Myotonic Dystrophy Type 1	06-05	CI
Harmony Biosciences Holdings, Inc. Appoints Kumar Budur as Executive Vice President and Chief Medical & Scientific Officer	05-03	CI
Harmony Biosciences Acquires Epygenix Therapeutics; Shares Rise	04-30	MT
Transcript : Harmony Biosciences Holdings, Inc., Q1 2024 Earnings Call, Apr 30, 2024	04-30
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	04-30	CI
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	04-30	CI
Earnings Flash (HRMY) HARMONY BIOSCIENCES Posts Q1 EPS $0.88, vs. Street Est of $0.78	04-30	MT
Harmony Biosciences Holdings, Inc. Reiterates Revenue Guidance for the Year 2024	04-30	CI
Harmony Biosciences, Bioprojet Enter Licensing Deal for Sleep Disorder Therapy	04-11	MT
Harmony Biosciences Begins Phase 3 Trial of Pitolisant to Treat Prader-Willi Syndrome Symptoms	04-03	MT
Harmony Biosciences Initiates Global Phase 3 Registrational Trial (Tempo Study) of Pitolisant in Patients with Prader-Willi Syndrome	04-03	CI
Harmony Biosciences Holdings Insider Sold Shares Worth $383,328, According to a Recent SEC Filing	03-19	MT
Transcript : Harmony Biosciences Holdings, Inc. Presents at Barclays 26th Annual Global Healthcare Conference 2024, Mar-12-2024 03:35 PM	03-12
Mizuho Securities Cuts Price Target on Harmony Biosciences to $40 From $42, Maintains Buy Rating	02-27	MT
Needham Cuts Price Target on Harmony Biosciences to $50 From $53, Maintains Buy Rating	02-23	MT
Harmony Biosciences Holdings' Q4 Adjusted Net Income Falls, Net Product Revenue Rises; 2024 Revenue Guidance Issued	02-22	MT
Transcript : Harmony Biosciences Holdings, Inc., Q4 2023 Earnings Call, Feb 22, 2024	02-22
Harmony Biosciences Holdings, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	02-22	CI
Tranche Update on Harmony Biosciences Holdings, Inc.'s Equity Buyback Plan announced on October 31, 2023.	02-22	CI

Chart Harmony Biosciences Holdings, Inc.

Duration

Period

Chart Harmony Biosciences Holdings, Inc.

More charts

Harmony Biosciences Holdings, Inc. is a commercial-stage pharmaceutical company. It is focused on developing and commercializing therapies for patients living with rare neurological diseases as well as patients living with other neurological diseases who have unmet medical needs. Its product, WAKIX (pitolisant), is a first-in-class molecule with a novel mechanism of action designed to enhance histamine signaling in the brain by binding to H3 receptors. Its WAKIX is developed for the treatment of excessive daytime sleepiness (EDS) in adult patients with narcolepsy and treatment of cataplexy in adult patients with narcolepsy. It also provides HBS-102, an investigational compound, which is a melanin-concentrating hormone receptor 1 (MCHR1) antagonist that targets MCH neurons in the brain. It also develops ZYN002, a pharmaceutically manufactured synthetic cannabidiol. It is also focused on the rare epilepsy franchise in its expanding late-stage pipeline of CNS assets: EPX-100 and EPX-200.

Sector

Pharmaceuticals

Calendar

2024-07-29 - Q2 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

Income Statement Evolution

More financial data

Ratings for Harmony Biosciences Holdings, Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

31.48 USD

Average target price

43.62 USD

Spread / Average Target

+38.58%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Other Pharmaceuticals

	1st Jan change	Capi.
HARMONY BIOSCIENCES HOLDINGS, INC.	-2.54%	1.79B
ELI LILLY AND COMPANY	+55.95%	819B
NOVO NORDISK A/S	+43.62%	638B
JOHNSON & JOHNSON	-6.98%	351B
MERCK & CO., INC.	+19.08%	329B
ABBVIE INC.	+9.05%	298B
ASTRAZENECA PLC	+16.30%	242B
ROCHE HOLDING AG	+2.41%	225B
NOVARTIS AG	+12.47%	217B
AMGEN INC.	+8.91%	168B

Other Pharmaceuticals